The White House on Wednesday said pharmaceutical firms risked damaging their reputations with big price hikes, but it sidestepped commenting directly on Mylan NV's decision to raise the price of its severe allergy treatment drug EpiPen.
from CBC | Health News http://ift.tt/2bgXP8i
Aucun commentaire:
Enregistrer un commentaire